GOFINTECH QUANT (00290) announced that on May 8, 2026, the company entered into a non-binding strategic cooperation memorandum of understanding with MedImage Bio (Suzhou) Life Science Technology Co., Ltd. The MOU outlines a strategic collaboration between the two parties.

According to the memorandum, the parties intend to cooperate under a milestone-based licensing model in the following areas: (i) Asset Licensing and Acquisition: The parties agreed to utilize a joint venture to co-operate MedImage Bio's quantum computing drug discovery system, which includes the QureGen AI and TyxonQ platforms, through licensing arrangements. They will further acquire the quantum AIDD platform and drug pipelines via milestone-based steps. (ii) Industrial Fund: The parties agreed to jointly initiate the establishment of a quantum frontier technology investment fund. This fund will invest in the biopharmaceutical and materials sectors, as well as in the development of specialized quantum chips for other frontier areas of quantum technology. (iii) Quantum Computing Center: The parties will jointly establish a quantum computing center in Hong Kong, in accordance with relevant policies. The center will focus on research and development of quantum computing application technologies and related innovation work.

As a diversified financial services platform, the group has consistently sought to explore various cooperative opportunities in the fields of quantum technology and AI. In April 2026, the group and MedImage Bio established a joint venture in the British Virgin Islands, marking the group's strategic expansion into the field of quantum AI drug discovery.

The Board of Directors believes the strategic cooperation provides the group with opportunities to: (a) further explore developments in cutting-edge technology areas and the potential integration of its resources with MedImage Bio's infrastructure, such as the QureGen AI and TyxonQ platforms; and (b) target areas like drug discovery and new material design by leveraging MedImage Bio's existing drug pipelines and quantum AI computing assets, thereby exploring ways to enrich the group's potential revenue streams.

Furthermore, the Board believes that the potential integration of corresponding management and technical resources with MedImage Bio will enhance the group's technological competitiveness in the era of "quantum-AI" convergence. The strategic cooperation will enable the group to leverage its management resources alongside MedImage Bio's technical expertise.